{"title":"家庭 OCT 和持续给药方法的完美结合:家庭 OCT 和持续给药:完美结合。","authors":"Nancy M Holekamp","doi":"10.1016/j.ajo.2024.10.031","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To provide a perspective on the management of neovascular age-related macular degeneration (nAMD) patients using a combination of sustained drug delivery strategies and remote monitoring technology.</p><p><strong>Design: </strong>Evidence-based perspective METHODS: Review of the literature and experience of the author RESULTS: Currently there are many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the Port Delivery System with ranibizumab and the Home OCT are FDA approved and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by nAMD patients. Other sustained drug delivery strategies such as tyrorinse kinase inhibitor delivery systems and viral vector mediated anti-VEGF intraocular bio-factory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches.</p><p><strong>Conclusion: </strong>The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Home OCT and Sustained Delivery Approaches, a Perfect Marriage: Home OCT and Sustained Drug Delivery: A Perfect Marriage.\",\"authors\":\"Nancy M Holekamp\",\"doi\":\"10.1016/j.ajo.2024.10.031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To provide a perspective on the management of neovascular age-related macular degeneration (nAMD) patients using a combination of sustained drug delivery strategies and remote monitoring technology.</p><p><strong>Design: </strong>Evidence-based perspective METHODS: Review of the literature and experience of the author RESULTS: Currently there are many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the Port Delivery System with ranibizumab and the Home OCT are FDA approved and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by nAMD patients. Other sustained drug delivery strategies such as tyrorinse kinase inhibitor delivery systems and viral vector mediated anti-VEGF intraocular bio-factory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches.</p><p><strong>Conclusion: </strong>The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.</p>\",\"PeriodicalId\":7568,\"journal\":{\"name\":\"American Journal of Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ajo.2024.10.031\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajo.2024.10.031","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:结合持续给药策略和远程监控技术,为新生血管性年龄相关性黄斑变性(nAMD)患者的管理提供一个视角:设计:基于证据的视角 方法:回顾文献和作者的经验 结果:目前,视网膜领域正在进行多项研究,旨在实现安全、有效的持续给药和有效的远程监控。目前,使用雷尼珠单抗的端口给药系统和家庭 OCT 已获得 FDA 批准,可供临床医生使用。对现有数据的回顾和一个病例表明,这些组合技术有可能减轻 nAMD 患者目前的注射负担和监测负担。其他持续给药策略,如酪氨酸激酶抑制剂给药系统和病毒载体介导的抗血管内皮生长因子眼内生物工厂模型,尚未获准用于临床。在临床试验中使用这些技术的早期经验预示着使用各种持续给药方法进行远程监测的潜在优势和可能的局限性:结论:将持续给药和经过验证的远程监测结合起来使用,预示着当前的 nAMD 治疗格局将发生重大变化,并有可能减轻患者的注射和监测负担,同时优化患者的治疗效果。
Home OCT and Sustained Delivery Approaches, a Perfect Marriage: Home OCT and Sustained Drug Delivery: A Perfect Marriage.
Purpose: To provide a perspective on the management of neovascular age-related macular degeneration (nAMD) patients using a combination of sustained drug delivery strategies and remote monitoring technology.
Design: Evidence-based perspective METHODS: Review of the literature and experience of the author RESULTS: Currently there are many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the Port Delivery System with ranibizumab and the Home OCT are FDA approved and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by nAMD patients. Other sustained drug delivery strategies such as tyrorinse kinase inhibitor delivery systems and viral vector mediated anti-VEGF intraocular bio-factory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches.
Conclusion: The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.
期刊介绍:
The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect.
The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports.
Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.